


Tomo 2/2 07-94715
OLARTE RAISBECK
OLARTE RAISBECK FRIERI MOURE & CASTRO LTDA.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-094715-00001-0000

Fecha: 2007-10-05 16:04:02 Dep. 2020 NUECREACION
Tra. 11 PATENTEIYI Eve: 378 FASENACIONAL
Act. 329 CTOINFORMACION Folios: 14

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES

E. S. D.

Ref.: Expediente No. 07-094.715

Solicitud de Patente de Invención titulada: "NUEVOS COMPUESTOS".

Solicitante: GLAXO GROUP LIMITED.

MEMORIAL DE ALCANCE

J. IAN RAISBECK, mayor de edad y vecino de Bogotá, identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad solicitante, me permito dar alcance a la solicitud de patente en referencia presentada ante ese Despacho el pasado 13 de septiembre de 2007 en los siguientes términos:

1. Me permito aportar junto al presente memorial, para efectos de cumplir en el requerimiento de presentar una cesión, la declaración de los inventores presentada ante la oficina internacional bajo la Regla 4.17 del PCT.
2. Finalmente, me permito adjuntar copia del Informe de Búsqueda Internacional, junto con la opinión escrita.

Atentamente,

J. IAN RAISBECK
C. C. N° 79.376.996 de Bogotá
T.P. 135.799 CSJ

Anexo: Declaración de inventores
Informe de Búsqueda Internacional

Sheet No.

Box No. VIII(iii) DECLARATION: ENTITLEMENT TO CLAIM PRIORITY

The declaration must conform to the standardized wording provided for in Section 213; see Notes to Boxes Nos. VIII, VIII(i) to (v) (in general) and the specific Notes to Box No. VIII(iii) and 51bis.1(a)(iii)

Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application specified below, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii)):

in relation to this international application No. PCT/US2006/010855

GLAXO GROUP LIMITED is entitled to claim priority of earlier application No. 60/665315 filed in the United States of America by virtue of the following:

an assignment from

CALLAHAN, James Francis of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, to
GLAXO GROUP LIMITED dated 17 April 2006

BOEHM, Jeffrey C. of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, to GLAXO
GROUP LIMITED dated 13 April 2006

COOPER, Anthony William James of Gunnels Wood Road, Stevenage, Hertfordshire SG12NY to
GLAXO GROUP LIMITED dated 02 May 2006

LIVIA, Stefano of Gunnels Wood Road, Stevenage, Hertfordshire SG12NY to GLAXO GROUP
LIMITED dated 02 May 2006

NEVINS, Neysa of 709 Swedeland Road, King of Prussia, Pennsylvania 19406 to GLAXO
GROUP LIMITED dated 16 May 2006

WAN, Zehong of 709 Swedeland Road, King of Prussia, Pennsylvania 19406 to GLAXO
GROUP LIMITED dated 17 April 2006

NORTON, Beth A. of Research Triangle Park, North Carolina 27709 to GLAXO GROUP
LIMITED dated 07 June 2006

This declaration is made for the purposes of all designations, except the designation of the United States of America.

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII(iii)".

Form PCT/RO/101 (declaration sheet (iii)) (March 2001; reprint January 2003)

See Notes to the request form

Sheet No.

Box No. VIII(ii) DECLARATION: ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT

The declaration must conform to the standardized wording provided for in Section 212; see Notes to Boxes Nos. VIII, VIII(i) to (v) (in general and the specific Notes to Box No. VIII(ii)). If this Box is not used, this sheet should not be included in the request.

Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate:

in relation to international application No. PCT/US2006/010855

GLAXO GROUP LIMITED is entitled to apply for and be granted a patent by virtue of the following:
an assignment from

CALLAHAN, James Francis of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, to
GLAXO GROUP LIMITED dated 17 April 2006

BOEHM, Jeffrey C. of 709 Swedeland Road, King of Prussia, Pennsylvania 19406, to GLAXO
GROUP LIMITED dated 13 April 2006

COOPER, Anthony William James of Gunnels Wood Road, Stevenage, Hertfordshire SG12NY to
GLAXO GROUP LIMITED dated 02 May 2006

LIVIA, Stefano of Gunnels Wood Road, Stevenage, Hertfordshire SG12NY to GLAXO GROUP
LIMITED dated 02 May 2006

NEVINS, Neysa of 709 Swedeland Road, King of Prussia, Pennsylvania 19406 to GLAXO
GROUP LIMITED dated 16 May 2006

WAN, Zehong of 709 Swedeland Road, King of Prussia, Pennsylvania 19406 to GLAXO
GROUP LIMITED dated 17 April 2006

NORTON, Beth A. of Research Triangle Park, North Carolina 27709 to GLAXO GROUP
LIMITED dated 07 June 2006

This declaration is made for the purposes of all designations except the designation of the United States of America.

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII(ii)".

Form PCT/RO/101 (declaration sheet (II)) (March 2001; reprint January 2003)

See Notes to the request form

Sheet No.

Box No. VIII(iv) DECLARATION: INVENTORSHIP (only for the purposes of the designation of the United States of America). The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VII, VIII(i) to (v) (in general) and the specific Notes to Box No. VIII(iv). If this Box is not used, this sheet should not be included in the request.

Declaration of Inventorship (Rules 4.17(iv) and 51bis.1(a)(iv))**for the purposes of the designation of the United States of America:**

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This application is directed to international application No. **PCT/US2006/010855** (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Application," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

Prior Applications:

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: JAMES FRANCIS CALLAHAN

Residence: 709 Swedeland Road, King of Prussia, PA, USA
(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: James Francis Callahan
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 17-Apr-2006
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: JEFFREY C. BOEHM

Residence: 709 Swedeland Road, King of Prussia, PA, USA
(city and either US state, if applicable, or country)

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Jeffrey C. Boehm
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 13-Apr-2006
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII(iv)".

Sheet No.

Continuation of Box No. VIII(i) to (v) Declaration

If the space is insufficient in any of Boxes Nos. VIII(i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII" (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.

Name: ANTHONY WILLIAM JAMES COOPER**Residence: Gunned Wood Road, Stevenage, Hertfordshire SG12NY****Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939****Citizenship: United Kingdom****Inventor's Signature:** [Signature]

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 2 May 06

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: STEFANO LIVIA**Residence: Gunned Wood Road, Stevenage, Hertfordshire SG12NY****Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939****Citizenship: United Kingdom****Inventor's Signature:** [Signature]

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 2 May 2006

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: NEYSA NEVINS**Residence: 709 Swedeland Road, King of Prussia, PA, USA****Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939****Citizenship: United States of America****Inventor's Signature:** _____

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: _____

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: ZEHONG WAN**Residence: 709 Swedeland Road, King of Prussia, PA, USA****Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939****Citizenship: China****Inventor's Signature:** _____

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: _____

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Form PCT/RO/101 (continuation sheet for declaration) (March 2001; reprint January 2003) See Notes to the request form

Sheet No.

Continuation of Box No. VIII(i) to (v) Declaration

If the space is insufficient in any of Boxes Nos. VIII(i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII" (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.

Name: ANTHONY WILLIAM JAMES COOPER

Residence: Gurnels Wood Road, Stevenage, Hertfordshire SG12NY

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United Kingdom

Inventor's Signature: _____

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: _____

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: STEFANO LIVIA

Residence: Gurnels Wood Road, Stevenage, Hertfordshire SG12NY

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United Kingdom

Inventor's Signature: _____

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: _____

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: NEYSA NEVINS

Residence: 709 Swedeland Road, King of Prussia, PA, USA

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Neysa Nevins

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 16-May-2006

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name: ZEHONG WAN

Residence: 709 Swedeland Road, King of Prussia, PA, USA

Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: China

Inventor's Signature: Zehong Wan

(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)

Date: 17-Apr-2006

(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Continuation of Box No. VIII(i) to (v) Declaration

If the space is insufficient in any of Boxes Nos. VIII(i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII" (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.

Name: Beth A. Norton

Residence: Five Moore Drive, Research Triangle Park, North Carolina 27709
(city and either US state, if applicable, or country)Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship: United States of America

Inventor's Signature: Beth A. Norton
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)Date: 14-June-2006
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name:

Residence:
(city and either US state, if applicable, or country)Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship:

Inventor's Signature:
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)Date:
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Name:

Residence:
(city and either US state, if applicable, or country)Mailing Address: GlaxoSmithKline, Corporate Intellectual Property - UW2220, P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Citizenship:

Inventor's Signature:
(if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent.)Date:
(of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

Form PCT/RO/101 (continuation sheet for declaration) (March 2001; reprint January 2003) See Notes to the request form

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To:
DARA L. DINNER
GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY, UW2220
709 SWEDELAND ROAD, P.O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

RECEIVED
GLAXOSMITHKLINE PCT

2007 SEP 25
NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT AND
THE WRITTEN OPINION OF THE INTERNATIONAL
SEARCHING AUTHORITY, OR THE DECLARATION

(PCT Rule 44.1)

Applicant's or agent's file reference PU61314	Date of mailing (day/month/year) 25 SEP 2007 FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US06/10855	International filing date (day/month/year) 24 March 2006 (24.03.2006)
Applicant GLAXOSMITHKLINE	

1. ☒ The applicant is hereby notified that the international search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.

Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 338.82.70.

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.
3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
- ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
 - ☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Reminders**


Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Authorized officer  Cecilia M. Jaisle Telephone No. 571-272-0700
---	---

742
243
606

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

743
X
244
60X

Applicant's or agent's file reference PU61314	FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/US06/10855	International filing date (day/month/year) 24 March 2006 (24.03.2006)	(Earliest) Priority Date (day/month/year) 25 March 2005 (25.03.2005)
Applicant GLAXOSMITHKLINE		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 3 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the Report

a. With regard to the language, the international search was carried out on the basis of:



the international application in the language in which it was filed.



a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))

b. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, see Box No. I.

2. ☐ Certain claims were found unsearchable (See Box No. II)

3. ☐ Unity of invention is lacking (See Box No. III)

4. With regard to the title,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

Please See Continuation Sheet

5. With regard to the abstract,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the drawings,

a. the figure of the drawings to be published with the abstract is Figure No. _____



as suggested by the applicant.



as selected by this Authority, because the applicant failed to suggest a figure.



as selected by this Authority, because this figure better characterizes the invention.

b. ☐ none of the figures is to be published with the abstract.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US06/10855

A. CLASSIFICATION OF SUBJECT MATTER

IPC: C07D 413/14(2006.01);471/04(2006.01);487/04(2006.01);A61K 31/519,31/5365

USPC: 514/264.11,234.2;544/117,279

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/264.11,234.2;544/117,279

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

24 August 2007 (24.08.2007)

Date of mailing of the international search report

25 SEP 2007

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Cecilia M. Jaigle

Telephone No. 571-272-0700

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:
DARA L. DINNER
GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY, UW2220
709 SWEDELAND ROAD, P.O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

PCT

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Applicant's or agent's file reference PU61314		Date of mailing (day/month/year) 25 SEP 2007
FOR FURTHER ACTION See paragraph 2 below		
International application No. PCT/US06/10855	International filing date (day/month/year) 24 March 2006 (24.03.2006)	Priority date (day/month/year) 25 March 2005 (25.03.2005)
International Patent Classification (IPC) or both national classification and IPC IPC: C07D 413/14(2006.01),471/04(2006.01),487/04(2006.01);A61K 31/519,31/5365 USPC: 514/234.2,264.11;544/117,279		
Applicant GLAXOSMITHKLINE		

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Date of completion of this opinion 24 August 2007 (24.08.2007)	Authorized Officer Cecilia M. Jaisle Telephone No. 571-272-0700
--	---	---

Form PCT/ISA/237 (cover sheet) (April 2005)

247746

72
610

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US06/10855

Box No. I Basis of this opinion

1. With regard to the language, this opinion has been established on the basis of:

- ☒ the international application in the language in which it was filed
- ☐ a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

- ☐ a sequence listing
- ☐ table(s) related to the sequence listing

b. format of material

- ☐ on paper
- ☐ in electronic form

c. time of filing/furnishing

- ☐ contained in the international application as filed.
- ☐ filed together with the international application in electronic form.
- ☐ furnished subsequently to this Authority for the purposes of search.

3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US06/10855

749 748
612

Box No. V Reasoned statement under Rule 43 *bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims <u>1-94</u>	YES
	Claims <u>NONE</u>	NO
Inventive step (IS)	Claims <u>1-94</u>	YES
	Claims <u>NONE</u>	NO
Industrial applicability (IA)	Claims <u>1-94</u>	YES
	Claims <u>NONE</u>	NO

2. Citations and explanations: